SCHEMBL4133213

SCHEMBL4133213

CCCCCCCCCCCCC/C=C/C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CETP P11597 4/20 1.00
THRB P10828 1/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
ASAH1 Q13510 2/20 0.78
TP53 P04637 2/20 0.75
CYP1A2 P05177 1/20 0.75
CYP2D6 P10635 1/20 0.75
MAPT P10636 1/20 0.75
CYP2C9 P11712 1/20 0.75
MAPK1 P28482 1/20 0.75
CYP2C19 P33261 1/20 0.75
ASAH2 Q9NR71 2/20 0.71
DEGS1 O15121 1/20 0.70
PLA2G4A P47712 4/20 0.68
ALDH1A1 P00352 2/20 0.64
KDM4E B2RXH2 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13863420 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22973496 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL5527047 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22911186 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22973426 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL24032894 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22973497 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22910831 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL22910800 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1
SCHEMBL14032326 1.00 CETP (1.00) CETPTHRBMEN1KMT2AASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121775140-A Application of ceramide and synthesis regulator thereof in regulation of porcine epidemic diarrhea virus infection 中国农业大学 2026-04-03 CN disclosed
US-12390490-B2 Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2025-08-19 US disclosed
CN-119654140-A Lipid nanoparticles comprising long chain ceramides and compositions for apoptosis comprising the same 禾大韩国有限公司 2025-03-18 CN disclosed
WO-2024210692-A1 HIGHLY WATER-DISPERSIBLE COMPOSITION HAVING HIGH CERAMIDE CONTENT 주식회사 무진메디 2024-10-10 WO disclosed
CN-117462461-A Skin barrier repairing composition, and cosmetics and application thereof 欧诗漫生物股份有限公司 2024-01-30 CN disclosed
US-20230392147-A1 MAMMALIAN CELLS FOR PRODUCING A SECRETED PROTEIN BOEHRINGER INGELHEIM INT (DE) 2023-12-07 US disclosed
US-20230372207-A1 CARBONATED AEROSOL EXTERNAL PREPARATION FOR SKIN KAO CORPORATION (JP) 2023-11-23 US disclosed
US-20230372207-A1 CARBONATED AEROSOL EXTERNAL PREPARATION FOR SKIN KAO CORPORATION (JP) 2023-11-23 US disclosed
US-20230240948-A1 METHOD FOR PRODUCING COATING KAO CORPORATION (JP) 2023-08-03 US disclosed
US-20230240948-A1 METHOD FOR PRODUCING COATING KAO CORPORATION (JP) 2023-08-03 US disclosed
US-7511010-B2 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration LABORATOIRES EXPANSCIENCE (FR) 2009-03-31 US disclosed
US-20090081148-A1 PROTECTION OF KERATINOUS FIBERS USING CERAMIDES AND/OR GLYCOCERAMIDES L'OREAL S.A. 2009-03-26 US disclosed
US-20090081148-A1 PROTECTION OF KERATINOUS FIBERS USING CERAMIDES AND/OR GLYCOCERAMIDES L'OREAL S.A. 2009-03-26 US disclosed
US-20090047231-A1 AQUEOUS HAIR COSMETIC COMPOSITION KAO CORPORATION (JP) 2009-02-19 US disclosed
US-20090047231-A1 AQUEOUS HAIR COSMETIC COMPOSITION KAO CORPORATION (JP) 2009-02-19 US disclosed
US-20080299063-A1 HAIR COSMETIC COMPOSITION KAO CORPORATION (JP) 2008-12-04 US disclosed
US-20080299063-A1 HAIR COSMETIC COMPOSITION KAO CORPORATION (JP) 2008-12-04 US disclosed
US-20080221017-A1 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration LABORATOIRES EXPANSCIENCE 2008-09-11 US disclosed
US-20080221017-A1 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration LABORATOIRES EXPANSCIENCE 2008-09-11 US disclosed
EP-1468666-B1 Hair shampoo composition KAO CORP (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12390490-B2 Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents SGMS1, SGMS2, SELENOI CETP 1633/4885THRB 3639/4885MEN1 69/4885
US-20080299063-A1 HAIR COSMETIC COMPOSITION H1-0, H1-3, H1-2 CETP 1482/4885THRB 1149/4885MEN1 314/4885
US-20230240948-A1 METHOD FOR PRODUCING COATING CUTA, KRT18, S100B CETP 132/4885THRB 3756/4885MEN1 2776/4885
US-20090081148-A1 PROTECTION OF KERATINOUS FIBERS USING CERAMIDES AND/OR GLYCOCERAMIDES KRT18, CERT1, CERS2 CETP 166/4885THRB 4842/4885MEN1 3014/4885
US-20090047231-A1 AQUEOUS HAIR COSMETIC COMPOSITION POLR1C, CUTA, POLH CETP 540/4885THRB 173/4885MEN1 1367/4885
US-20230372207-A1 CARBONATED AEROSOL EXTERNAL PREPARATION FOR SKIN CERT1, CERS2, SGMS2 CETP 42/4885THRB 4468/4885MEN1 3467/4885
US-20080221017-A1 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration MMP1, MMP13, MMP2 CETP 632/4885THRB 4422/4885MEN1 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.